AND HERE HE COMES FROM BRISTOL MEYERS SQUIBB: CETUXIMAB

CRYSTAL REGIMEN IN FIRST LINE KRAS MUTATION NEGATIVE (WILD TYPE) EGFR EXPRESSING METASTATIC COLORECTAL CANCER...


------------------------------------------------------------------------------------------------
                                                  Crystal regimen       vs     Folfiri alone

Median survival                         23.5 months             Vs    19.5 months

Objective response                           57%                  Vs    39%

Median PFS                                  9.5 months           Vs     8.1 months

-----------------------------------------------------------------------------------------------

higher chance to respond to treatment, and higher survival, when you add Cetuximab to FOLFIRI.

Side effects:

Acne-like RASH  86%  Vs 13%
Diarrhea      66%   Vs 60
Neutropenia   31%  Vs  24%

Making Acnee-like-rash the most specific side effect to cetuximab!  Why is a good question for the CRCBM.